36 results about "WNT5A" patented technology

The present invention provides a method for preparing a reference model for cancer relapse prediction that provides higher resolution grading than Gleason score alone. The method encompasses obtaining from different individuals a plurality of prostate carcinoma tissue samples of known clinical outcome representing different Gleason scores; selecting a set of signature genes having an expression pattern that correlates positively or negatively in a statistically significant manner with the Gleason scores; independently deriving a prediction score that correlates gene expression of each individual signature gene with Gleason score for each signature gene in said plurality of prostate carcinoma tissue samples; deriving a prostate cancer gene expression (GEX) score that correlates gene expression of said set of signature genes with the Gleason score based on the combination of independently derived prediction scores in the plurality of prostate cancer tissue samples; and correlating said GEX score with the clinical outcome for each prostate carcinoma tissue sample. A set of signature genes is provided that encompasses all or a sub-combination of GI_2094528, KIP2, NRG1, NBL1, Prostein, CCNE2, CDC6, FBP1, HOXC6, MKI67, MYBL2, PTTG1, RAMP, UBE2C, Wnt5A, MEMD, AZGP1, CCK, MLCK, PPAP2B, and PROK1. Also provided a methods for predicting the probability of relapse of cancer in an individual and methods for deriving a prostate cancer gene expression (GEX) score for a prostate carcinoma tissue sample obtained from an individual.

The present invention provides a method for preparing a reference model for cancer relapse prediction that provides higher resolution grading than Gleason score alone. The method encompasses obtaining from different individuals a plurality of prostate carcinoma tissue samples of known clinical outcome representing different Gleason scores; selecting a set of signature genes having an expression pattern that correlates positively or negatively in a statistically significant manner with the Gleason scores; independently deriving a prediction score that correlates gene expression of each individual signature gene with Gleason score for each signature gene in said plurality of prostate carcinoma tissue samples; deriving a prostate cancer gene expression (GEX) score that correlates gene expression of said set of signature genes with the Gleason score based on the combination of independently derived prediction scores in the plurality of prostate cancer tissue samples; and correlating said GEX score with the clinical outcome for each prostate carcinoma tissue sample. A set of signature genes is provided that encompasses all or a sub-combination of GI_2094528, KIP2, NRG1, NBL1, Prostein, CCNE2, CDC6, FBP1, HOXC6, MKI67, MYBL2, PTTG1, RAMP, UBE2C, Wnt5A, MEMD, AZGP1, CCK, MLCK, PPAP2B, and PROK1. Also provided a methods for predicting the probability of relapse of cancer in an individual and methods for deriving a prostate cancer gene expression (GEX) score for a prostate carcinoma tissue sample obtained from an individual.

Provided is a protein comprising an antibody binding site that binds to a sulfated epitope of a Wnt pathway protein that is not Wnt5A, Wnt11, or Wnt3a. Also provided is a composition comprising an isolated and purified Wnt pathway protein, where the protein is sulfated but not glycosylated. Additionally provided is a preparation of a Wnt pathway protein comprising at least one sulfation site and at least one glycosylation site, where all of the Wnt pathway protein in the preparation is glycosylated but not sulfated. Further provided is a composition comprising a peptide less than 75 amino acids or amino acid analogs, the peptide consisting of a fragment of a Wnt pathway protein, wherein the fragment is sulfated. A modified Wnt pathway protein comprising a sulfation site that is not present in the native Wnt pathway protein is also provided. Also provided is a method of detecting or quantifying a sulfated Wnt pathway protein in a preparation. Additionally, a modified Wnt pathway protein lacking a sulfation site that is present in the native Wnt pathway protein is provided. Also provided is methods of treating a subject having a disease exacerbated by Wnt activation. Additionally, a method of treating a subject having a disease exacerbated by Wnt inhibition is provided.

The invention discloses a serum-free medium for mesenchymal stem cells as well as a preparation method and applications of the serum-free medium. Cytokines in serum are replaced by adding EGF, PDGF, bFGF, beta-TGF, BMP-7 and wnt5a; lipids in serum are replaced by adding linoleic acid, linolenic acid and lecithin; through orthogonal design, the additives are compounded, and the good proliferation effect is obtained. In addition, the ingredients are definite, and the batch-to-batch differences are reduced; the potential risks of exogenous viruses and pathogenic factors are eliminated; the untoward effects of clinical research are reduced; and the application prospect is good.

Systems, methods, and computer readable media for diagnosing or characterizing epithelial cancer or its stages based on the level of expression of the Wnt5a gene or protein are provided. The level of nucleic acids encoding Wnt5a or the level of Wnt5a protein is measured in a tissue sample, and the level is compared with reference values. Methods for inducing senescence of an epithelial cancer cell are also provided.

Disclosed herein are methods of treating cancer in a subject, and methods for inhibiting growth, migration and / or invasion of a cancer cell in the subject, comprising administering to the subject a therapeutically effective amount of an antibody or antigen binding fragment thereof that downmodulates Fzd2. The antibody may specifically bind Fzd2, and may promote internalization of the Fzd2 receptor by the cancer cells and / or prevent ligand binding to Fzd2. Specific antibodies, and also specific portions of the Fzd2 molecule for antibody binding are disclosed. In one embodiment the antibody specifically binds to the epitope HGAEQICVGQNHSEDGAPAL (SEQ ID NO: 1). Specific cancers (e.g. late stage hepatocellular carcinoma), intended for treatment are provided, and include cancers that exhibit overexpression of Fzd2, and / or Wnt5a.

The invention discloses a marker for postpartum eclampsia diagnosis. The marker is one of WNT4 protein and WNT5A protein or a combination thereof. The invention also discloses a reagent for clinical diagnosis of postpartum eclampsia, wherein the reagent comprises one or both of a WNT4 antibody and a WNT5A antibody, an HRP rabbit anti-goat antibody and a beta-actin antibody. The detection reagent disclosed by the invention has the advantages of high sensitivity and high specificity and can be widely applied to preliminary investigation and health screening of postpartum eclampsia so as to provide reliable data to clinical diagnosis.

A WNT5A peptide or derivatives thereof in combination with one or more checkpoint inhibitors for use in treatment of cancer in a subject in need thereof. Furthermore, WNT5A peptides or derivatives thereof may be used in treatment of cancer in a subject, wherein the subject is responsive to immune checkpoint inhibitors.

Disclosed herein are methods of treating cancer in a subject, and methods for inhibiting growth, migration and / or invasion of a cancer cell in the subject, comprising administering to the subject a therapeutically effective amount of an antibody or antigen binding fragment thereof that downmodulates Fzd2. The antibody may specifically bind Fzd2, and may promote internalization of the Fzd2 receptor by the cancer cells and / or prevent ligand binding to Fzd2. Specific antibodies, and also specific portions of the Fzd2 molecule for antibody binding are disclosed. In one embodiment the antibody specifically binds to the epitope HGAEQICVGQNHSEDGAPAL (SEQ ID NO: 1). Specific cancers (e.g. late stage hepatocellular carcinoma), intended for treatment are provided, and include cancers that exhibit overexpression of Fzd2, and / or Wnt5a.

The present invention provides a novel human Wnt5a-NL nucleic acid recombinant and its preparation method and application. The human Wnt5a-NL nucleic acid recombinant of the present invention is a recombinant plasmid obtained by constructing the human Wnt5a protein truncated gene encoding gene shown in SEQ ID NO: 1 on a eukaryotic expression vector. Experiments have shown that human Wnt5a-NL nucleic acid recombinant injection mice can inhibit inflammation and bone destruction, and can be developed for the treatment of rheumatoid arthritis and other diseases. The nucleic acid recombinant provided by the invention belongs to the therapeutic plasmid, which can provide a new treatment approach and idea for rheumatoid arthritis and other diseases. The nucleic acid recombinant has good therapeutic effect, simple preparation, low cost, good stability and convenient storage, and is suitable for large-scale production.